A new class of antiretroviral medication for adult patients was approved by the FDA in March of 2018. Trogarzo (Ibalizumab-uiyk) is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes.”
Description
Ibalizumab-uiyk is an anti-CD4 monoclonal antibody of immunoglobulin G (IgG) produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells.
Indication
Ibalizumab-uiyk is a CD4-directed post-attachment HIV-1 inhibitor, used in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Mechanism of action
Ibalizumab-uiyk is a recombinant humanized monoclonal antibody that binds to a site on the CD4 molecule of a helper T-cell. The presence of the Ibalizumab-uiyk attached to the CD4 molecule mechanically interferes with the complete viral attachment and fusion of the T-cell and HIV membranes. Without fusion, the HIV-1 capsule and genome cannot enter the CD4+ T cells. By binding to domain 2 of CD4 and interfering with post-attachment steps required for entry of HIV-1 virus particles into host cells, Ibalizumab prevents viral transmission via cell-cell fusion.
Ibalizumab video series 3: Ibalizumab mechanism of action. Theratechnologies Inc. YouTube video
Reference
fda. (2018). FDA approves new HIV treatment for patients who have limited treatment options. Press Announcements . https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options.
.